Phenominer Database Results (74 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Formula Average Type Value Units SEM SD Method Method Site Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Experiment Notes Record ID Study ID
ACI/SegHsd prostate tumorous lesion number control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900.0 days 12 5.3 null ex vivo light microscopy 0 65822 341
ACI/SegHsd prostate gland wet weight control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate mass male 900.0 days 12 1.54 g post excision weight measurement 0 65828 341
ACI/SegHsd mammary tumor number 17 beta-estradiol (27.5 mg) (between 193 and 199 days) Schaffer BS, et al., Cancer Res. 2006 Aug 1;66(15):7793-800 mammary gland integrity trait female 143.0 days-259.0 days 22 8.8 null 1.4 6.57 manual palpation method 0.0 crystalline implant 11382 81
ACI/SegHsd post-insult time to mammary tumor formation 17 beta-estradiol (27.5 mg) (between 99 and 197 days) Shull JD, et al., Carcinogenesis. 1997 Aug;18(8):1595-601 mammary gland integrity trait female 160.0 days-260.0 days 21 serial mean 145.0 d manual palpation method mammary gland 0.0 66104 76
ACI/SegHsd well differentiated malignant colorectal tumor surface area measurement 1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days) De Miglio MR, et al., Carcinogenesis. 2007 May 17;. colorectal integrity trait not specified  days 20 43.9 mm2 1.52 6.8 ex vivo caliper method 0.0 caliper 70390 1378
ACI/SegHsd area of ventral prostate occupied by tumorous lesions to total ventral prostate area ratio control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900.0 days 12 1.61 % ex vivo light microscopy with digital image analysis 0.0 67946 341
ACI/SegHsd area of ventral prostate occupied by tumorous lesions with solid structure to total ventral prostate area ratio control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900.0 days 12 1.09 % 0.38 1.31 ex vivo light microscopy with digital image analysis 0.0 109891 341
ACI/SegHsd percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98.0 days-200.0 days 4 0.0 % ex vivo visual assessment 0.0 peripheral nervous system integrity trait 84524 1178
ACI/SegHsd hematocrit arterial catheter implantation (for 1 days) then controlled hemorrhage (for 0.4 hours) Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. erythrocyte quantity male 89.0 days-95.0 days 9 30.6 % 1.1 3.3 microhematocrit tube assay with visual assessment 0.0 initial hematocrit, final hematocrit, change in hematocrit 107249 3077
ACI/SegHsd mean arterial blood pressure arterial catheter implantation (for 1 days) Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. arterial blood pressure trait male 89.0 days-95.0 days 9 116.0 mmHg 5.0 15.0 vascular fluid filled catheter 300.0 5-second intervals Initial MAP 107329 3077
ACI/SegHsd post-insult time to mammary tumor formation 17 beta-estradiol (27.5 mg) (between 99 and 197 days) Shull JD, et al., Carcinogenesis. 1997 Aug;18(8):1595-601 mammary gland integrity trait female 160.0 days-260.0 days 21 median 143.0 d manual palpation method mammary gland 0.0 66111 76
ACI/SegHsd mammary tumor number 17 beta-estradiol (27.5 mg) (for 196 days) Kurz SG, et al., Endocrinology. 2008 Apr 17 mammary gland integrity trait female 259.0 days 21 7.0 null 1.16 5.3 necropsy 11368 75
ACI/SegHsd post-insult time to mammary tumor formation 17 beta-estradiol (27.5 mg) (for 196 days) Kurz SG, et al., Endocrinology. 2008 Apr 17 mammary gland integrity trait female  days-259.0 days 21 145.0 d manual palpation method 0 median 11375 75
ACI/SegHsd percentage of study population developing mammary tumors during a period of time control condition Shull JD, et al., Carcinogenesis. 1997 Aug;18(8):1595-601 mammary gland integrity trait female 201.0 days-518.0 days 3 0.0 % manual palpation method mammary gland 0 11378 76
ACI/SegHsd post-insult time to mammary tumor formation 17 beta-estradiol (27.5 mg) (between 147 and 195 days) Shull JD, et al., Endocrinology 2001 Dec;142(12):5124-30 mammary gland integrity trait female 206.0 days-264.0 days 31 141.0 d 4.85 27.0 manual palpation method mean 11748 144
ACI/SegHsd pituitary gland wet weight sham surgical control condition (between 193 and 199 days) Shull JD, et al., Mamm Genome. 2007 Sep 18;. pituitary gland mass female 252.0 days-266.0 days 10 0.01 g 0.0 0.0 post excision weight measurement pituitary gland 0 13090 331
ACI/SegHsd body weight control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. body mass male 900.0 days 12 null 419.6 g body weighing method method not specified, assumed to be digital scale 13301 341
ACI/SegHsd benign colorectal tumor surface area measurement 1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days) De Miglio MR, et al., Carcinogenesis. 2007 May 17;. colorectal integrity trait not specified  days 20 8.2 mm2 1.03 4.6 ex vivo caliper method 0.0 caliper 70388 1378
ACI/SegHsd pituitary gland wet weight diethylstilbestrol (5 mg) (for 84 days) and surgical implantation Strecker TE, et al., Genetics 2005 Jan 31;. pituitary gland mass male 147.0 days 14 0.08 g 0.0 0.01 post excision weight measurement 0.0 subcutaneous implant 84 days diethylstilbestrol 69101 1122
ACI/SegHsd pituitary gland wet weight sham surgical control condition Strecker TE, et al., Genetics 2005 Jan 31;. pituitary gland mass male 147.0 days 7 0.01 g 0.0 0.0 post excision weight measurement 0.0 69104 1122
ACI/SegHsd percentage of study population developing benign colorectal tumors during a period of time 1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days) De Miglio MR, et al., Carcinogenesis. 2007 May 17;. colorectal integrity trait not specified  days 20 75.0 % ex vivo light microscopy 0.0 70376 1378
ACI/SegHsd benign colorectal tumor number 1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days) De Miglio MR, et al., Carcinogenesis. 2007 May 17;. colorectal integrity trait not specified  days 20 1.5 null 0.31 1.4 ex vivo light microscopy 0.0 70378 1378
ACI/SegHsd thymus wet weight control condition Gould KA, et al., Mamm Genome. 2006 May;17(5):451-64. thymus mass male 147.0 days 9 150.0 mg 15.33 46.0 post excision weight measurement 0.0 69097 1121
ACI/SegHsd thymus wet weight diethylstilbestrol (5 mg) (for 84 days) and surgical implantation Gould KA, et al., Mamm Genome. 2006 May;17(5):451-64. thymus mass male 147.0 days 13 166.0 mg 6.1 22.0 post excision weight measurement 0.0 subcutaneous implant 84 days diethylstilbestrol 69099 1121
ACI/SegHsd percentage of study population developing experimental autoimmune neuritis during a period of time peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98.0 days-200.0 days 4 0.0 % ex vivo visual assessment 0.0 peripheral nervous system integrity trait 84474 1178
ACI/SegHsd percentage of study population developing subcutaneous tumors during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. hypodermis integrity trait male 900.0 days 12 0.0 % necropsy 0.0 CMO:0003387 percentage of study population developing subcutaneous tumors during a period of time 106887 341
ACI/SegHsd percentage of study population developing ventral prostate tumorous lesions with a solid structure during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900.0 days 12 92.0 % ex vivo light microscopy 0.0 109885 341
ACI/SegHsd number of ventral prostate tumorous lesions with solid structure control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900.0 days 12 3.0 null 0.75 2.6 ex vivo light microscopy 0.0 109887 341
ACI/SegHsd percentage of study population developing ventral prostate tumorous lesions with round, irregular size nuclei during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900.0 days 12 100.0 % ex vivo light microscopy 0.0 109957 341
ACI/SegHsd post-insult time to mammary tumor formation 17 beta-estradiol (27.5 mg) (between 193 and 199 days) Schaffer BS, et al., Cancer Res. 2006 Aug 1;66(15):7793-800 mammary gland integrity trait female 143.0 days-259.0 days 22 median 133.0 d manual palpation method 0 crystalline implant 65763 81
ACI/SegHsd binary logarithm of pituitary gland wet weight surgical implantation then 17 beta-estradiol (27.5 mg) (between 193 and 199 days) Shull JD, et al., Mamm Genome. 2007 Sep 18;. pituitary gland mass female 252.0 days-266.0 days 9 7.15 null 0.12 0.36 post excision weight measurement pituitary gland 0 logarithm of pituitary wet weight 65770 331
ACI/SegHsd percentage of study population developing ventral prostate tumorous lesions during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900.0 days 12 100.0 % ex vivo light microscopy 0 65825 341
ACI/SegHsd ventral prostate gland wet weight control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. ventral prostate mass male 900.0 days 12 0.32 g post excision weight measurement 0.0 65826 341
ACI/SegHsd percentage of study population developing pituitary tumors during a period of time 17 beta-estradiol (27.5 mg) (between 146 and 202 days) Shull JD, et al., Carcinogenesis. 1997 Aug;18(8):1595-601 pituitary gland integrity trait female 207.0 days-265.0 days 21 100.0 % ex vivo visual assessment 0 65551 76
ACI/SegHsd percentage of study population developing mammary tumors during a period of time bilateral ovariectomy then 17 beta-estradiol (27.5 mg) (for 140 days) Shull JD, et al., Carcinogenesis. 1997 Aug;18(8):1595-601 mammary gland integrity trait female 201.0 days-203.0 days 11 0.0 % manual palpation method mammary gland 0 11379 76
ACI/SegHsd percentage of study population developing leukemia during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. leukocyte integrity trait male 900.0 days 12 0.0 % ex vivo light microscopy 0 leukemia incidence 66143 341
ACI/SegHsd percentage of study population developing poorly differentiated malignant colorectal tumors during a period of time 1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days) De Miglio MR, et al., Carcinogenesis. 2007 May 17;. colorectal integrity trait not specified  days 20 15.0 % ex vivo light microscopy 0.0 70384 1378
ACI/SegHsd poorly differentiated malignant colorectal tumor surface area measurement 1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days) De Miglio MR, et al., Carcinogenesis. 2007 May 17;. colorectal integrity trait not specified  days 20 38.7 mm2 1.81 8.1 ex vivo caliper method 0.0 caliper 70392 1378
ACI/SegHsd pituitary gland wet weight diethylstilbestrol (5 mg) (for 84 days) and surgical implantation Strecker TE, et al., Genetics 2005 Jan 31;. pituitary gland mass male 147.0 days 28 0.07 g 0.0 0.01 post excision weight measurement 0.0 subcutaneous implant 84 days diethylstilbestrol 69105 1122
ACI/SegHsd percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (0.25 mg/ml) and Freund's incomplete adjuvant (50 %) Dahlman I, et al., Hum Mol Genet 1999 Nov;8(12):2183-90. central nervous system integrity trait not specified 70.0 days-145.0 days 21 5.0 % in vivo visual assessment 0.0 69970 1279
ACI/SegHsd percentage of study population developing bilateral testis tumors during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. testis integrity trait male 900.0 days 12 25.0 % ex vivo light microscopy 0.0 necropsy bilateral testis tumor incidence 67948 341
ACI/SegHsd absolute change in thymus weight control condition Gould KA, et al., Mamm Genome. 2006 May;17(5):451-64. thymus mass male 147.0 days 9 268.0 mg post excision weight measurement 0.0 69098 1121
ACI/SegHsd volume of blood removed to total prehemorrhagic blood volume ratio arterial catheter implantation (between 1 and 1.2 days) then controlled hemorrhage (for 0.4 hours) Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. blood amount male 89.0 days-95.0 days 9 5.83 mL/100 g of body weight 56.9 % 0.5 1.5 body weighing method 0.0 volume of blood removed to total prehemorrhagic blood volume ratio (CMO:0003663) 109123 3077
ACI/SegHsd area of ventral prostate occupied by tumorous lesions with round, irregular size nuclei to total ventral prostate area ratio control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900.0 days 12 1.57 % 0.38 1.31 ex vivo light microscopy with digital image analysis 0.0 109963 341
ACI/SegHsd percentage of study population developing mammary tumors during a period of time 17 beta-estradiol (27.5 mg) (between 147 and 195 days) Shull JD, et al., Endocrinology 2001 Dec;142(12):5124-30 mammary gland integrity trait female 206.0 days-264.0 days 31 100.0 % manual palpation method 0 mean 66112 144
ACI/SegHsd binary logarithm of pituitary gland wet weight sham surgical control condition (between 193 and 199 days) Shull JD, et al., Mamm Genome. 2007 Sep 18;. pituitary gland mass female 252.0 days-266.0 days 10 3.13 null 0.06 0.19 post excision weight measurement pituitary gland 0 logarithm of pituitary wet weight 65771 331
ACI/SegHsd both testes wet weight control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. testis mass male 900.0 days 12 2.81 g post excision weight measurement 0 65820 341
ACI/SegHsd area of individual prostate tumorous lesion control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900.0 days 12 1.78 mm2 ex vivo light microscopy with digital image analysis 0 65838 341
ACI/SegHsd percentage of study population developing mammary tumors during a period of time 17 beta-estradiol (27.5 mg) (for 197 days) Shull JD, et al., Carcinogenesis. 1997 Aug;18(8):1595-601 mammary gland integrity trait female 160.0 days-260.0 days 21 100.0 % manual palpation method mammary gland 0 65549 76
ACI/SegHsd pituitary gland wet weight surgical implantation then 17 beta-estradiol (27.5 mg) (between 193 and 199 days) Shull JD, et al., Mamm Genome. 2007 Sep 18;. pituitary gland mass female 252.0 days-266.0 days 9 0.15 g 0.01 0.04 post excision weight measurement pituitary gland 0 13093 331
ACI/SegHsd percentage of study population developing well differentiated malignant colorectal tumors during a period of time 1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days) De Miglio MR, et al., Carcinogenesis. 2007 May 17;. colorectal integrity trait not specified  days 20 20.0 % ex vivo light microscopy 0.0 70380 1378
ACI/SegHsd thymus wet weight control condition Gould KA, et al., Mamm Genome. 2006 May;17(5):451-64. thymus mass male 63.0 days 9 419.0 mg 13.33 40.0 post excision weight measurement 0.0 69096 1121
ACI/SegHsd water intake drink rate to body weight ratio arterial catheter implantation (for 1 days) Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. drinking behavior trait male 89.0 days-95.0 days 9 0.36 ml/d/kg 0.08 0.24 drink intake measuring method 0.0 arterial catheter implantation 1 days water intake/body weight ratio Water consumed (g) postsurgery per 100 g BW 107154 3077
ACI/SegHsd hematocrit arterial catheter implantation (for 1 days) then controlled hemorrhage (for 0 hours) Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. erythrocyte quantity male 89.0 days-95.0 days 9 35.1 % 2.1 6.3 microhematocrit tube assay with visual assessment 0.0 initial hematocrit, final hematocrit, change in hematocrit 107231 3077
ACI/SegHsd absolute change in hematocrit arterial catheter implantation (for 1 days) then controlled hemorrhage (between 0 and 0.4 hours) Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. erythrocyte quantity male 89.0 days-95.0 days 9 4.5 % 2.5 7.5 microhematocrit tube assay with visual assessment 0.0 start vs end of hemorrhage initial hematocrit, final hematocrit, change in hematocrit 107265 3077
ACI/SegHsd percentage of study population developing unilateral renal agenesis during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. kidney integrity trait male 900.0 days 12 24.0 % necropsy 0.0 106885 341
ACI/SegHsd area of individual ventral prostate tumorous lesion with a solid structure control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900.0 days 12 1.17 mm2 0.36 1.25 ex vivo light microscopy with digital image analysis 0.0 109889 341
ACI/SegHsd number of ventral prostate tumorous lesions with round, irregular size nuclei control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900.0 days 12 5.1 null 0.69 2.4 ex vivo light microscopy 0.0 109959 341
ACI/SegHsd area of individual ventral prostate tumorous lesion with round, irregular size nuclei control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900.0 days 12 1.73 mm2 0.36 1.24 ex vivo light microscopy with digital image analysis 0.0 109961 341
ACI/SegHsd percentage of study population developing mammary tumors during a period of time 17 beta-estradiol (27.5 mg) (between 193 and 199 days) Schaffer BS, et al., Cancer Res. 2006 Aug 1;66(15):7793-800 mammary gland integrity trait female 143.0 days-259.0 days 22 94.0 % manual palpation method 0 crystalline implant 65764 81
ACI/SegHsd percentage of study population developing testis tumors during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. testis integrity trait male 900.0 days 12 92.0 % ex vivo light microscopy 0.0 testis tumor incidence 65840 341
ACI/SegHsd percentage of study population developing pituitary tumors during a period of time bilateral ovariectomy then 17 beta-estradiol (27.5 mg) (for 140 days) Shull JD, et al., Carcinogenesis. 1997 Aug;18(8):1595-601 pituitary gland integrity trait female 201.0 days-203.0 days 11 100.0 % ex vivo visual assessment 0 65561 76
ACI/SegHsd mammary tumor number control condition Kurz SG, et al., Endocrinology. 2008 Apr 17 mammary gland integrity trait female 259.0 days 4 0.0 null necropsy 11367 75
ACI/SegHsd mammary tumor number 17 beta-estradiol (27.5 mg) (between 99 and 197 days) Shull JD, et al., Carcinogenesis. 1997 Aug;18(8):1595-601 mammary gland integrity trait female 160.0 days-260.0 days 20 5.6 null necropsy 0.0 tumor size reach 1-1.5 cm 11377 76
ACI/SegHsd post-insult time to mammary tumor formation 17 beta-estradiol (27.5 mg) (between 193 and 199 days) Schaffer BS, et al., Cancer Res. 2006 Aug 1;66(15):7793-800 mammary gland integrity trait female 143.0 days-259.0 days 22 136.0 d 6.0 28.14 manual palpation method 0.0 crystalline implant 11383 81
ACI/SegHsd post-insult time to mammary tumor formation 17 beta-estradiol (27.5 mg) (between 147 and 195 days) Shull JD, et al., Endocrinology 2001 Dec;142(12):5124-30 mammary gland integrity trait female 206.0 days-264.0 days 31 median 140.0 d manual palpation method median 11750 144
ACI/SegHsd mammary tumor number 17 beta-estradiol (27.5 mg) (between 144 and 195 days) Shull JD, et al., Endocrinology 2001 Dec;142(12):5124-30 mammary gland integrity trait female 203.0 days-264.0 days 34 3.9 null 0.6 3.5 manual palpation method 0 11752 144
ACI/SegHsd liver wet weight control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. liver mass male 900.0 days 12 null 11.3 g post excision weight measurement method not specified, assumed to be digital scale 13303 341
ACI/SegHsd spleen wet weight control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. spleen mass male 900.0 days 12 null 0.8 g post excision weight measurement method not specified, assumed to be digital scale 13305 341
ACI/SegHsd pituitary gland wet weight sham surgical control condition Strecker TE, et al., Genetics 2005 Jan 31;. pituitary gland mass male 147.0 days 6 0.01 g 0.0 0.0 post excision weight measurement 0.0 69100 1122
ACI/SegHsd percentage of study population developing unilateral renal agenesis during a period of time control condition Shull JD, et al., Mamm Genome. 2006 Jul;17(7):751-9. Epub 2006 Jul 14. kidney integrity trait female  days 96 13.5 % necropsy 0.0 69372 1157
ACI/SegHsd percentage of study population developing unilateral renal agenesis during a period of time control condition Shull JD, et al., Mamm Genome. 2006 Jul;17(7):751-9. Epub 2006 Jul 14. kidney integrity trait male  days 87 5.7 % necropsy 0.0 69374 1157
ACI/SegHsd well differentiated malignant colorectal tumor number 1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days) De Miglio MR, et al., Carcinogenesis. 2007 May 17;. colorectal integrity trait not specified  days 20 0.28 null 0.04 0.16 ex vivo light microscopy 0.0 70381 1378
ACI/SegHsd food intake weight to body weight ratio arterial catheter implantation (for 1 days) Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53. eating behavior trait male 89.0 days-95.0 days 9 4.5 g/d/100g 0.5 1.5 food intake measuring method 0.0 arterial catheter implantation 1 days Food consumed (g) postsurgery per 100 g BW 107119 3077